Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of p53 (17-26), fitc labeled in China, also supports custom service. Welcome to wholesale bulk high quality p53 (17-26), fitc labeled from our factory. Contact us for more details.
| Description | p53 (17-26) mimics the key α-helical motif by which the tumor suppressor p53 binds the E3 ligase MDM2 (which inhibits and degrades p53). FITC labeling enables fluorescence-polarization affinity measurement and competitive screening of Nutlin-class MDM2-p53 inhibitors. |
| Structure type | Linear 10-mer (p53 17-26, FITC-labeled) |
| Solubility | Readily soluble in water/PBS |
| Storage | Powder, −20°C, dry, light-protected |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Salt Form | Length (aa) |
| p53 (17-26), FITC Labeled [N-terminally FITC-Labeled Human p53 N-terminal MDM2-Binding Domain] | FITC-ETFSDLWKLL; FITC-p53(17-26); human p53 N-terminal transactivation-domain MDM2-binding peptide, FITC-labeled; PEP-FITCp53-01 | FITC-labeled peptide, human p53 tumor suppressor, N-terminal transactivation domain (TAD), MDM2-p53 interaction, MDM2 antagonist screening, fluorescence polarization (FP) assay, tryptophan-containing light-sensitive peptide, oncology drug-screening tool peptide | Linear 10-mer, sequence FITC-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-OH (FITC-ETFSDLWKLL), derived from residues 17-26 of the N-terminal transactivation domain (TAD) of human p53 (NM_000546); the N-terminal alpha-amine of Glu is directly coupled to FITC (fluorescein isothiocyanate) via a thiourea bond (net addition C21H11NO5S, no spacer); C-terminal free Leu-OH; contains the three critical MDM2-binding hydrophobic residues Phe19 (position 3 in the peptide), Trp23 (position 7) and Leu26 (position 10)-insertion of these three residues into the MDM2 hydrophobic pocket is the core of p53-MDM2 binding; contains 1 Trp (strongly hydrophobic, light-sensitive, oxidation-prone), 2 Leu, 1 Phe; side-chain charges: Glu -1, Asp -1, Lys +1, C-terminus -1, net charge approx -2; no Cys/Arg; FITC fluorescence λex≈494 nm/λem≈520 nm. | C81H101N13O22S | 1639.69 | 1640.83 | Free acid (C-terminal -COOH); N-terminal FITC direct label; contains 1 Trp-must be protected from light; TFA/acetate forms available on request | 10 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage | Short-term Storage | Solution Stability | Solid Powder Stability |
| PEP-FITCp53-01 | Yellow to tan powder (FITC label; contains Trp) | Store at -20°C, sealed, desiccated, protected from light (amber vial/aluminum foil wrap), ~1-2 years; recommended to flush with argon/nitrogen and aliquot to avoid repeated freeze-thaw. Contains 1 Trp + the FITC fluorophore-MUST be kept in the dark at all times (foil wrap / amber vial) to prevent tryptophan photo-oxidation and fluorescence quenching. | 2-8°C, light-protected, for ~2 weeks; working aliquots at -20°C, light-protected; avoid repeated freeze-thaw; prepare fresh as needed. | Short peptide rich in hydrophobic residues (2 Leu + 1 Phe + 1 Trp), with moderate water solubility-pre-dissolve in a small volume of DMSO (≤5% final), then dilute in assay buffer (e.g., 20 mM Tris-HCl pH 7.4 / 150 mM NaCl). The Trp residue is sensitive to photo-oxidation, strong oxidants and heat-work under subdued light. FITC channel λex≈494 nm/λem≈520 nm. In MDM2-binding / fluorescence-polarization (FP) assays, peptide binding to recombinant MDM2(17-125) increases polarization, enabling competition screening of Nutlin-like MDM2 antagonists; working peptide concentration typically nM-µM. Avoid DTT/TCEP-type strong reducing agents (although there is no Cys, they can accelerate Trp/FITC oxidation). | solid stable ~1-2 years at -20°C, sealed, desiccated, light-protected and under inert gas; both Trp and FITC are light-sensitive-weigh promptly after opening and reseal (wrap in foil); solution-state stability is poor-prepare fresh and do not store diluted solutions long-term. |
Functional Description
| Product Code | Frontend Short Summary | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Pathways |
| PEP-FITCp53-01 | N-terminally direct-FITC-labeled human p53 N-terminal transactivation-domain peptide (residues 17-26; ETFSDLWKLL, 10-mer), retaining the MDM2-binding hot-spot residues Phe19/Trp23/Leu26-for MDM2-p53 interaction studies, MDM2 antagonist (Nutlin-class) screening and fluorescence-polarization (FP) binding assays; contains Trp, light-protected throughout. | Human p53 is one of the most important tumor suppressors, acting as a transcription factor that controls cell-cycle arrest, DNA repair, apoptosis and senescence. The p53 N-terminal transactivation domain (TAD, ~residues 1-73) binds the hydrophobic pocket of the E3 ubiquitin ligase MDM2 (the human homolog HDM2), leading to p53 ubiquitination and degradation; p53 is inactivated in ~50% of human tumors, while MDM2 is overexpressed in many sarcomas/leukemias, continuously suppressing p53. Residues 17-26 of the p53 TAD (ETFSDLWKLL) are the MDM2-binding core; the three hydrophobic residues Phe19, Trp23 and Leu26 (the FXXWXXL motif) insert deeply into the MDM2 N-terminal hydrophobic pocket. Small molecules that mimic this alpha-helix conformation (e.g., Nutlin-3, RG7112, idasanutlin) compete for the MDM2 pocket, releasing p53 and restoring its antitumor activity-a key oncology therapeutic strategy. N-terminal FITC labeling preserves the peptide's binding to the MDM2 N-terminal domain while adding a green fluorescent channel (λex≈494 nm/λem≈520 nm). Main applications: (1) fluorescence polarization (FP) assay-FITC-p53(17-26) bound to recombinant MDM2(17-125) tumbles more slowly and shows elevated polarization; compounds that compete for the MDM2 pocket reduce polarization, making this a classic homogeneous assay for high-throughput screening (HTS) of MDM2-p53 interaction inhibitors; (2) fluorescence anisotropy / FP binding kinetics and IC50 determination; (3) evaluation of how MDM2 mutants or structural analogs affect p53 peptide affinity; (4) in vitro competitive ELISA or fluorescence-magnetic binding assays; (5) evaluation of alpha-helix mimetics and stapled peptides against MDM2. KEY NOTES: the peptide contains 1 Trp (position 23), which is inherently light- and oxidation-sensitive; combined with the FITC fluorophore, keep it under foil, store under inert gas and prepare working solutions fresh; the short peptide is relatively hydrophobic and requires DMSO pre-dissolution; FP assays need purified recombinant MDM2 protein, and include proper controls (e.g., F19A/W23A mutant peptide) and peptide/protein molar ratios. | MDM2-p53 interaction, MDM2 antagonist/Nutlin-class drug screening, homogeneous fluorescence-polarization (FP) assay, oncology drug discovery, p53 tumor-suppressor pathway, stapled peptide/alpha-helix mimetic evaluation, in vitro binding-affinity measurement, high-throughput screening (HTS) | MDM2 (HDM2) N-terminal hydrophobic pocket (binds p53 TAD Phe19/Trp23/Leu26); FITC fluorescence channel λex≈494 nm/λem≈520 nm |
Hot Tags: p53 (17-26), fitc labeled, China p53 (17-26), fitc labeled manufacturers, suppliers, factory
